Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy

About 3% of all cancer patients suffer from carcinoma of unknown primary site (CUP). In spite of its rarity, we will encounter them. While CUPs manifest a wide variety of clinical presentations, they have often resulted in poor prognosis. Although platinum/taxane combination chemotherapy, e.g. carbo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yasui, Hirotoshi, Sato, Kazuhide, Takeyama, Yoshihiro, Kato, Toshio, Hashimoto, Hiroyuki, Fukui, Yasutaka, Yoshihisa, Nagashima, Maeda, Matsuyoshi, Gonda, Hideo, Suzuki, Ryujiro
Formato: Artigo
Idioma:Inglês
Publicado em: S. Karger AG 2014
Assuntos:
Published online: August, 2014
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4178322/
https://ncbi.nlm.nih.gov/pubmed/25298764
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000366268
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados